Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Wednesday

Voyager Therapeutics (NASDAQ:VYGR) is anticipated to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $16.58 million for the quarter.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $4.22 on Monday. Voyager Therapeutics has a 52 week low of $4.00 and a 52 week high of $10.66. The company has a market cap of $230.54 million, a PE ratio of 5.94 and a beta of 0.91. The firm has a 50 day simple moving average of $5.37 and a 200 day simple moving average of $6.10.

Insiders Place Their Bets

In other news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 10,778 shares of company stock valued at $58,548 over the last three months. 4.53% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on VYGR. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wedbush reissued an “outperform” rating and issued a $9.00 price target (down from $11.00) on shares of Voyager Therapeutics in a research report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Monday, January 27th. Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $5.73 target price for the company. Finally, Citigroup initiated coverage on Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $15.72.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.